Developed by Jiangsu Hengrui Medicine Co., Ltd., it emerged from the need to treat HER2-positive breast cancers, which are often more aggressive and less responsive to hormonal therapy [45]. This evidence concerns the gene ERBB2 and breast carcinoma.